Inhibition of IL-6 signaling attenuates vascular damage caused by HIF1a activation
Protection against endothelial damage is recognized as a frontline approach to preventing the progression of cytokine release syndrome (CRS). Accumulating evidence has demonstrated that interleukin-6 (IL-6) promotes vascular endothelial damage during CRS, although the molecular mechanisms remain to be fully elucidated. Targeting IL-6 receptor signaling delays CRS progression; however, current options are limited by persistent inhibition of the immune system. Here, we show that endothelial IL-6 trans-signaling promoted vascular damage and inflammatory responses via hypoxia-inducible factor-1a (HIF1a)?induced glycolysis. Using pharmacological inhibitors targeting HIF1a activity or mice with the genetic ablation of gp130 in the endothelium, we found that inhibition of IL-6R?HIF1a signaling in endothelial cells protected against vascular injury caused by septic damage and provided survival benefit in a mouse model of sepsis. In addition, we developed a short half-life anti-IL-6R antibody (silent anti-IL-6R antibody) and found that it was highly effective at augmenting survival for sepsis and severe burn by strengthening the endothelial glycocalyx and reducing cytokine storm, and vascular leakage. Together, our data advance the role of endothelial IL-6 trans-signaling in the progression of CRS and indicate a potential therapeutic approach for burns to address the lack of burn-specific treatments. Overall design: HUVECs were stimulated by 100 ng/ml of LPS plus 100 ng/ml of soluble IL-6R for 6 hours, and then  total RNA were extracted.